Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Phase 2
Terminated
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Registration Number
- NCT00061646
- Lead Sponsor
- Abbott
- Brief Summary
The primary objective of this Phase II study is to assess the safety, pharmacokinetics and effectiveness of ABT-510 in combination with standard carboplatin/paclitaxel chemotherapy in subjects with stage IIIb or IV NSCLC.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Progression free survival One year
- Secondary Outcome Measures
Name Time Method Overall survival One year Response rate One year
Trial Locations
- Locations (4)
Oncology-Hematology Group of South Florida
🇺🇸Miami, Florida, United States
University of Chicago
🇺🇸Chicago, Illinois, United States
The West Cancer Clinic
🇺🇸Memphis, Tennessee, United States
University of Wisconsin
🇺🇸Madison,, Wisconsin, United States
Oncology-Hematology Group of South Florida🇺🇸Miami, Florida, United States